Remedy with SR18662 noticeably decreases growth and proliferation of CRC cells. SR18662 exhibits enhanced efficacy in lessening viability of numerous CRC cell lines. Circulation cytometry analysis adhering to SR18662 treatment exhibits an increase in cells captured in both S or G2/M phases of the cell cycle and a major boost https://franciszekh207xdh0.shoutmyblog.com/profile